Transient Tachypnea of newborn tachypnea ,
Conditions
Interventions
inhalation of corticosteroids (budesonide 2 ml,
0.25 mg/ml suspension for nebulizer,
AstraZeneca AB,
Södertälje,
Sweden),
the first dose was administered within 6 h of birth and the second dose was given
12 h later.,placebo
Experimental Drug,Placebo Comparator No treatment
inhaled budesonide,placebo
Sponsors
mohamed shawky elfarargy
Ghada Alashmawy
Eligibility
Sex/Gender
All
Age
No minimum to 28 Days
Inclusion criteria
Inclusion criteria: full term neonates
Exclusion criteria
Exclusion criteria: preterm neonates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transient Tachypnea of the newborn at 3 days after end of the intervention( inhaled budesonide) pulse oximeter to measure peripheral oxygen saturation | — |
Secondary
| Measure | Time frame |
|---|---|
| none none none | — |
Countries
Egypt
Contacts
Public Contactmohamed elfarargy
Tanta University Hospital
Outcome results
None listed